Atreca Competitors

Heron Therapeutics (NASDAQ:HRTX) and Atreca (NASDAQ:BCEL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Heron Therapeutics and Atreca's net margins, return on equity and return on assets.

Institutional and Insider Ownership

99.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 69.6% of Atreca shares are owned by institutional investors. 12.9% of Heron Therapeutics shares are owned by company insiders. Comparatively, 9.9% of Atreca shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Heron Therapeutics and Atreca's revenue, earnings per share and valuation.

Atreca has lower revenue, but higher earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Heron Therapeutics and Atreca, as reported by MarketBeat.com.

Heron Therapeutics presently has a consensus target price of $26.00, indicating a potential upside of 44.52%. Atreca has a consensus target price of $28.75, indicating a potential upside of 145.31%. Given Atreca's stronger consensus rating and higher possible upside, analysts plainly believe Atreca is more favorable than Heron Therapeutics.

Risk & Volatility

Heron Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Atreca has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500.

Summary

Atreca beats Heron Therapeutics on 8 of the 13 factors compared between the two stocks.

Atreca (NASDAQ:BCEL) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Profitability

This table compares Atreca and Supernus Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

69.6% of Atreca shares are owned by institutional investors. Comparatively, 96.1% of Supernus Pharmaceuticals shares are owned by institutional investors. 9.9% of Atreca shares are owned by insiders. Comparatively, 6.6% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Atreca and Supernus Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Supernus Pharmaceuticals has higher revenue and earnings than Atreca. Atreca is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Atreca and Supernus Pharmaceuticals, as provided by MarketBeat.

Atreca currently has a consensus price target of $28.75, indicating a potential upside of 145.31%. Supernus Pharmaceuticals has a consensus price target of $37.50, indicating a potential upside of 18.93%. Given Atreca's higher probable upside, equities research analysts plainly believe Atreca is more favorable than Supernus Pharmaceuticals.

Volatility and Risk

Atreca has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500.

Summary

Supernus Pharmaceuticals beats Atreca on 9 of the 12 factors compared between the two stocks.

Atreca (NASDAQ:BCEL) and Myovant Sciences (NYSE:MYOV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Profitability

This table compares Atreca and Myovant Sciences' net margins, return on equity and return on assets.

Insider & Institutional Ownership

69.6% of Atreca shares are owned by institutional investors. Comparatively, 33.8% of Myovant Sciences shares are owned by institutional investors. 9.9% of Atreca shares are owned by insiders. Comparatively, 3.9% of Myovant Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Atreca and Myovant Sciences' top-line revenue, earnings per share (EPS) and valuation.

Myovant Sciences is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Atreca and Myovant Sciences, as provided by MarketBeat.

Atreca currently has a consensus price target of $28.75, indicating a potential upside of 145.31%. Myovant Sciences has a consensus price target of $31.1667, indicating a potential upside of 64.21%. Given Atreca's stronger consensus rating and higher probable upside, equities research analysts plainly believe Atreca is more favorable than Myovant Sciences.

Volatility and Risk

Atreca has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Comparatively, Myovant Sciences has a beta of 2.99, indicating that its stock price is 199% more volatile than the S&P 500.

Summary

Atreca beats Myovant Sciences on 8 of the 11 factors compared between the two stocks.

Atreca (NASDAQ:BCEL) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Profitability

This table compares Atreca and ADC Therapeutics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

69.6% of Atreca shares are owned by institutional investors. Comparatively, 40.9% of ADC Therapeutics shares are owned by institutional investors. 9.9% of Atreca shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Atreca and ADC Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Atreca has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Atreca and ADC Therapeutics, as provided by MarketBeat.

Atreca currently has a consensus price target of $28.75, indicating a potential upside of 145.31%. ADC Therapeutics has a consensus price target of $47.50, indicating a potential upside of 103.34%. Given Atreca's stronger consensus rating and higher probable upside, equities research analysts plainly believe Atreca is more favorable than ADC Therapeutics.

Summary

Atreca beats ADC Therapeutics on 7 of the 11 factors compared between the two stocks.

Atreca (NASDAQ:BCEL) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Profitability

This table compares Atreca and Harmony Biosciences' net margins, return on equity and return on assets.

Insider & Institutional Ownership

69.6% of Atreca shares are owned by institutional investors. Comparatively, 50.2% of Harmony Biosciences shares are owned by institutional investors. 9.9% of Atreca shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Atreca and Harmony Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of recent ratings and price targets for Atreca and Harmony Biosciences, as provided by MarketBeat.

Atreca currently has a consensus price target of $28.75, indicating a potential upside of 145.31%. Harmony Biosciences has a consensus price target of $51.6667, indicating a potential upside of 84.52%. Given Atreca's higher probable upside, equities research analysts plainly believe Atreca is more favorable than Harmony Biosciences.

Summary

Atreca beats Harmony Biosciences on 4 of the 6 factors compared between the two stocks.

Atreca (NASDAQ:BCEL) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Profitability

This table compares Atreca and Prelude Therapeutics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

69.6% of Atreca shares are owned by institutional investors. Comparatively, 76.2% of Prelude Therapeutics shares are owned by institutional investors. 9.9% of Atreca shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Atreca and Prelude Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of recent ratings and price targets for Atreca and Prelude Therapeutics, as provided by MarketBeat.

Atreca currently has a consensus price target of $28.75, indicating a potential upside of 145.31%. Prelude Therapeutics has a consensus price target of $54.25, indicating a potential upside of 52.22%. Given Atreca's stronger consensus rating and higher probable upside, equities research analysts plainly believe Atreca is more favorable than Prelude Therapeutics.

Summary

Atreca beats Prelude Therapeutics on 4 of the 7 factors compared between the two stocks.